Stock Research for ALPMY

ALPMY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALPMY Stock Chart & Research Data

The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALPMY Due diligence Resources & Stock Charts

The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALPMY Detailed Price Forecast - CNN Money CNN View ALPMY Detailed Summary - Google Finance
Yahoo View ALPMY Detailed Summary - Yahoo! Finance Zacks View ALPMY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ALPMY Trends & Analysis - Trade-Ideas Barrons View ALPMY Major Holders - Barrons
NASDAQ View ALPMY Call Transcripts - NASDAQ Seeking View ALPMY Breaking News & Analysis - Seeking Alpha
Spotlight View ALPMY Annual Report - CompanySpotlight.com OTC Report View ALPMY OTC Short Report - OTCShortReport.com
TradeKing View ALPMY Fundamentals - TradeKing Charts View ALPMY SEC Filings - Bar Chart
WSJ View Historical Prices for ALPMY - The WSJ Morningstar View Performance/Total Return for ALPMY - Morningstar
MarketWatch View the Analyst Estimates for ALPMY - MarketWatch CNBC View the Earnings History for ALPMY - CNBC
StockMarketWatch View the ALPMY Earnings - StockMarketWatch MacroAxis View ALPMY Buy or Sell Recommendations - MacroAxis
Bullish View the ALPMY Bullish Patterns - American Bulls Short Pains View ALPMY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ALPMY Stock Mentions - StockTwits PennyStocks View ALPMY Stock Mentions - PennyStockTweets
Twitter View ALPMY Stock Mentions - Twitter Invest Hub View ALPMY Investment Forum News - Investor Hub
Yahoo View ALPMY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALPMY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ALPMY - SECform4.com Insider Cow View Insider Transactions for ALPMY - Insider Cow
CNBC View ALPMY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALPMY - OTC Markets
Yahoo View Insider Transactions for ALPMY - Yahoo! Finance NASDAQ View Institutional Holdings for ALPMY - NASDAQ


Stock Charts

FinViz View ALPMY Stock Insight & Charts - FinViz.com StockCharts View ALPMY Investment Charts - StockCharts.com
BarChart View ALPMY Stock Overview & Charts - BarChart Trading View View ALPMY User Generated Charts - Trading View




Latest Financial News for ALPMY


Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Posted on Wednesday August 22, 2018

The companies now expect the ARCHES trial to end late this year, ahead of the previously anticipated completion date of April 2020, and the EMBARK trial to complete by mid-2020, earlier than the prior goal of March 2021. Both trials are testing Xtandi in men with hormone-sensitive prostate cancer. Xtandi is already approved in the United States to treat castration-resistant prostate cancer and brought Pfizer revenue of $171 million in the latest reported quarter.


[$$] Astellas Pharma Buys U.K.'s Quethera
Posted on Friday August 10, 2018

Astellas Pharma Inc. said Friday it acquired Quethera Ltd., a U.K. company focused on developing treatments for ocular disorders such as glaucoma.


Astellas Announces Acquisition of Quethera
Posted on Friday August 10, 2018

TOKYO and CAMBRIDGE, England, Aug. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., "Astellas") and Quethera Limited (CEO: Peter Widdowson, Ph.D., "Quethera") today announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom, that is focused on developing novel treatments for ocular disorders, such as glaucoma.


Astellas Is Considering Selling Europe Assets to Raise Cash
Posted on Wednesday July 18, 2018

Astellas Pharma Inc. is considering a sale of some central and eastern European assets as the Japanese drugmaker seeks to trim its portfolio and raise cash, according to people familiar with the matter. Astellas is working with Jefferies Financial Group Inc. on the potential disposal, which includes Russian assets and has drawn interest from private equity firms and other pharmaceutical companies, the people said, asking not to be identified because the deliberations are private. The portfolio under review includes drugs to prevent infections and pain treatments, the people said.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.